# α-Klotho

> The aging-associated protein whose circulating ectodomain is the FGF23 co-receptor — a recombinant glycoprotein, studied in phosphate balance and kidney disease.

- Also known as: alpha-Klotho, Klotho, soluble Klotho, sKlotho, KL
- Class: Longevity
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/alpha-klotho

## Overview

α-Klotho (gene KL) is a type I transmembrane protein. The full chain is 1,012 residues (UniProt Q9UEF7): a short signal, a large extracellular region of two glycosidase-like domains (KL1 and KL2), a single transmembrane span, and a short cytoplasmic tail. Proteases shed the extracellular piece into blood and cerebrospinal fluid; that soluble ectodomain, roughly Glu34–Ser981, is the form supplied as recombinant “soluble klotho.” It is not an approved medicine. It is also not β-klotho, the separate gene (KLB) that pairs with FGF21.

Kuro-o and colleagues (Nature, 1997) found klotho by accident: mice with a disrupted promoter aged fast — shortened lifespan, arterial calcification, skin atrophy, and osteoporosis — and restoring the gene prevented that picture. The protein those mice lacked is a membrane glycoprotein expressed mainly in the kidney distal tubule and the choroid plexus. The circulating activity is the ectodomain, cut loose by ADAM proteases and related sheddases. A separately spliced isoform contains only KL1 and is a minor species next to the shed two-domain form.

The function that made the protein tractable is phosphate, not a generic “anti-aging” activity. Membrane and soluble α-klotho both assemble with FGF receptors so that FGF23 can signal (Kurosu et al., and Urakawa et al., Journal of Biological Chemistry 2006). FGF23 then lowers renal phosphate reabsorption. Klotho-deficient and FGF23-deficient mice look alike, which is why the two are read as one axis. In chronic kidney disease that axis is disordered, and recombinant soluble klotho is studied as a way to put the co-receptor back — still investigational.

The research material is a glycoprotein, not a synthetic peptide. The naked ectodomain polypeptide is about 110 kDa; N-glycosylation pushes the circulating and recombinant protein to about 120–130 kDa on SDS-PAGE, and the mass and charge depend on the cell line that made it (CHO versus HEK). A product labeled only “klotho” can be the full ectodomain or the shorter KL1-only splice form (~65–70 kDa). β-Klotho is a different protein and the co-receptor for FGF21, so an identity test has to say which gene was expressed.

## Mechanism

Obligate co-receptor with FGF receptors for fibroblast growth factor 23. The Klotho–FGFR complex lets FGF23 lower phosphate reabsorption in the kidney and suppress vitamin D activation. The shed ectodomain retains co-receptor activity. A weaker, FGF23-independent glycosidase-like activity toward ion-channel and transporter glycans is also reported; the catalytic glutamates of a true family-1 glycosidase are not both present.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular weight | 130000 Da |
| UniProt | [Q9UEF7](https://www.uniprot.org/uniprotkb/Q9UEF7) |

## Research areas

Studied in: Aging, Phosphate metabolism, FGF23 signaling, Chronic kidney disease.

## Key research

- Aging phenotype — insertional disruption of the mouse gene produced a rapid-aging syndrome, and the gene was named klotho (Kuro-o et al., Nature 1997).
- FGF23 co-receptor — α-klotho converts FGF receptors into a high-affinity receptor for FGF23, coupling the protein to renal phosphate excretion.
- Soluble ectodomain — ADAM shedding releases a circulating form that keeps co-receptor activity; this is the species produced as recombinant soluble klotho (UniProt Q9UEF7, extracellular region).
- Kidney disease — disordered Klotho/FGF23 signaling is studied as a driver of disordered mineral metabolism in chronic kidney disease. Supplementation remains investigational.
- Not β-klotho — KLB is the FGF21 co-receptor. The two proteins are not interchangeable, and a long-acting brand suffix does not turn one into the other.

## Storage, handling & synthesis

**Storage.** Recombinant soluble α-klotho is a research glycoprotein. Store the lyophilized protein frozen, dry, and protected from light. After reconstitution keep it cold and avoid repeated freeze–thaw.

**Handling.** Handle as a large glycosylated protein: limit agitation and heat, which promote aggregation. Confirm the construct before use — full ectodomain versus the KL1-only splice, and α-klotho versus β-klotho — because the name on a vial is not the specification.

**Synthesis.** α-Klotho is not a solid-phase peptide. The soluble research material is the extracellular region (UniProt Q9UEF7, approximately residues 34–981) expressed in mammalian cells so it is N-glycosylated. The polypeptide mass is about 110 kDa; the glycosylated protein migrates at about 120–130 kDa, and sialylation — and therefore charge — differs between CHO and HEK production. The KL1-only splice is a different, smaller protein (~65–70 kDa). Identity is the expression construct and the glycan pattern, not a single molecular formula.

## FAQs

### What is α-klotho?

α-Klotho is a kidney- and choroid-plexus-enriched transmembrane protein. Its shed extracellular domain circulates and is the co-receptor that lets FGF23 regulate phosphate. Recombinant soluble klotho is that ectodomain, produced in mammalian cells.

### How is soluble klotho different from the membrane protein?

The membrane protein is the full 1,012-residue chain. Soluble klotho is the extracellular piece (about Glu34–Ser981) released by proteases. A minor spliced form contains only the first of the two extracellular domains. Glycosylation puts the two-domain soluble protein near 120–130 kDa.

### Is α-klotho the same as β-klotho?

No. β-Klotho is a separate gene, KLB, and it is the co-receptor for FGF21. α-Klotho pairs with FGF23. A vial marked only “klotho” has not said which one it is.

### Is this medical advice?

No — this is a research and educational reference. Soluble klotho is investigational and is not an approved medicine.

## Latest research

Recent trials and publications mentioning α-Klotho, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Creatine and Muscle Health in Madrid's Walking Footballers.](https://clinicaltrials.gov/study/NCT07891936) — NOT_YET_RECRUITING · NA · NCT07891936
- [Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease](https://clinicaltrials.gov/study/NCT06071143) — COMPLETED · PHASE1 · NCT06071143
- [Dysregulation of the Soluble α-Klotho-FGF23 Axis in Hashimoto's Thyroiditis: A Case-Control Study](https://clinicaltrials.gov/study/NCT07453290) — COMPLETED · NCT07453290
- [A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia](https://clinicaltrials.gov/study/NCT07571928) — ACTIVE_NOT_RECRUITING · PHASE1, PHASE2 · NCT07571928
- [Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)](https://clinicaltrials.gov/study/NCT04936282) — ACTIVE_NOT_RECRUITING · PHASE4 · NCT04936282
- [Safety and Efficacy of Klotho and Follistatin Gene Therapy](https://clinicaltrials.gov/study/NCT07285629) — COMPLETED · EARLY_PHASE1 · NCT07285629

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/alpha-klotho
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.